| scholarly article | Q13442814 |
| P50 | author | Curt D. Sigmund | Q40187956 |
| Carmen Halabi | Q79322700 | ||
| Frank M Faraci | Q86046795 | ||
| P2093 | author name string | Henry L Keen | |
| Yau-Sheng Tsai | |||
| Gary L Baumbach | |||
| Mary L Modrick | |||
| Nobuyo Maeda | |||
| Cynthia M Lynch | |||
| Willem J de Lange | |||
| Andreas M Beyer | |||
| Shams M Ghoneim | |||
| Thomas D Gerhold | |||
| P2860 | cites work | Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension | Q22011018 |
| Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice | Q28588279 | ||
| Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice | Q28590182 | ||
| The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells | Q31921949 | ||
| Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone | Q34324049 | ||
| Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect | Q35750683 | ||
| Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma | Q35835330 | ||
| Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? | Q36144641 | ||
| Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. | Q36509300 | ||
| Activation of peroxisome proliferator-activated receptor gamma by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst | Q38363547 | ||
| Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. | Q42536498 | ||
| Role of sex differences and effects of endothelial NO synthase deficiency in responses of carotid arteries to serotonin | Q43576448 | ||
| Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells | Q43646691 | ||
| Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides | Q43704020 | ||
| Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma | Q43993728 | ||
| Enhanced vasoconstrictor responses in eNOS deficient mice. | Q44535308 | ||
| PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice | Q44743365 | ||
| Structure of cerebral arterioles in mice deficient in expression of the gene for endothelial nitric oxide synthase | Q45075501 | ||
| Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes | Q45214949 | ||
| PPARgamma in endothelial cells influences high fat diet-induced hypertension | Q46438590 | ||
| Selective cerebral vascular dysfunction in Mn-SOD-deficient mice. | Q46973266 | ||
| Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells | Q47922823 | ||
| Cerebral arteriolar structure in mice overexpressing human renin and angiotensinogen | Q48414343 | ||
| Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase | Q48504517 | ||
| Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension | Q73696239 | ||
| PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease | Q74598459 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 867-871 | |
| P577 | publication date | 2008-02-19 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling | |
| P478 | volume | 51 |
| Q42728134 | A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system |
| Q43100241 | A second chance for a PPARγ targeted therapy? |
| Q33772466 | Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta. |
| Q39116577 | Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke |
| Q34598561 | Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia |
| Q41880978 | Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. |
| Q51445939 | Chronic renal failure alters endothelial function in cerebral circulation in mice. |
| Q92654920 | Conditional deletion of smooth muscle Cullin-3 causes severe progressive hypertension |
| Q37139653 | Context-dependent effects of SOCS3 in angiotensin II-induced vascular dysfunction and hypertension in mice: mechanisms and role of bone marrow-derived cells |
| Q29347284 | Contrasting vascular effects caused by loss of Bardet-Biedl syndrome genes |
| Q90747615 | Contributions of Aging to Cerebral Small Vessel Disease |
| Q56999967 | Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer's disease: An update |
| Q34407931 | Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR. |
| Q37430999 | Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production |
| Q37686890 | Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? |
| Q36837948 | Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle |
| Q37411594 | Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. |
| Q59798063 | Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia |
| Q34691864 | Effect of PPARγ inhibition during pregnancy on posterior cerebral artery function and structure |
| Q37395673 | Effects of the use of assisted reproduction and high-caloric diet consumption on body weight and cardiovascular health of juvenile mouse offspring |
| Q27342480 | Endothelial PPAR-γ Protects Against Vascular Thrombosis by Downregulating P-Selectin ExpressionSignificance |
| Q33642053 | Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. |
| Q36972995 | Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. |
| Q37997802 | Free radical biology of the cardiovascular system |
| Q38890930 | Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease |
| Q47710820 | Genetic Interference With Endothelial PPAR-γ (Peroxisome Proliferator-Activated Receptor-γ) Augments Effects of Angiotensin II While Impairing Responses to Angiotensin 1-7. |
| Q34892807 | Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism |
| Q35014033 | HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells |
| Q37034439 | Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation |
| Q36510633 | Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction |
| Q34051403 | Interference with peroxisome proliferator-activated receptor-γ in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction. |
| Q46188427 | Investigation of the effect of telmisartan on experimentally induced peripheral nerve injury in rats |
| Q42626934 | Leaky vessels: how the brain deals with pregnancy under pressure |
| Q38163612 | Mechanism of the anti-platelet effect of natural bioactive compounds: role of peroxisome proliferator-activated receptors activation. |
| Q36839870 | Microvascular Dysfunction and Cognitive Impairment. |
| Q38318147 | Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. |
| Q38012354 | NADPH oxidases as therapeutic targets in ischemic stroke. |
| Q37335663 | Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia |
| Q42428542 | Nitro-oleic acid inhibits angiotensin II-induced hypertension |
| Q37406290 | PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension |
| Q26863678 | PPAR-γ -- a possible drug target for complicated pregnancies |
| Q37179467 | PPARgamma and its ligands: therapeutic implications in cardiovascular disease. |
| Q24642728 | PPARs and the cardiovascular system |
| Q34099314 | PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats |
| Q38606230 | PPARγ Regulation in Hypertension and Metabolic Syndrome. |
| Q37686110 | PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice |
| Q47739408 | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair |
| Q37943863 | Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease |
| Q35994295 | Peroxisome proliferator-activated receptor-γ protects against vascular aging |
| Q35636191 | Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease |
| Q36076407 | Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice |
| Q34979773 | Protecting against vascular disease in brain |
| Q42008239 | Protective Actions of PPAR-gamma Activation in Renal Endothelium |
| Q36372517 | Protective Role for Tissue Inhibitor of Metalloproteinase-4, a Novel Peroxisome Proliferator-Activated Receptor-γ Target Gene, in Smooth Muscle in Deoxycorticosterone Acetate-Salt Hypertension. |
| Q46528028 | Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. |
| Q35169517 | Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ. |
| Q92522882 | RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity |
| Q34315697 | Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation |
| Q34046462 | Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension |
| Q27315042 | Smooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and Function |
| Q42778982 | Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase |
| Q37781280 | The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease |
| Q36745113 | The adaptation of the cerebral circulation to pregnancy: mechanisms and consequences |
| Q57159033 | The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation |
| Q35118380 | The role of oxidative stress and NADPH oxidase in cerebrovascular disease |
| Q45929326 | The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. |
| Q34836065 | The role of reactive oxygen species in microvascular remodeling |
| Q37725077 | Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention |
| Q46412969 | Vascular smooth muscle cell peroxisome proliferator-activated receptor γ protects against endothelin-1-induced oxidative stress and inflammation. |
| Q33692662 | Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension |
| Q86029497 | Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling |
Search more.